[1] STREBEL PM, ORENSTEIN WA.Measles[J]. N Engl J Med, 2019, 381(4):349-357. [2] WORLD HEALTH ORGANIZATION.Measles[EB/OL].[2023-07-15].https://www.who.int/zh/news-room/fact-sheets/detail/measles. [3] 中华人民共和国国家卫生与健康委员会. 麻疹诊疗方案(2024年版)[EB/OL]. http://www.nhc.gov.cn/ylyjs/pqt/202407/4662eb54f6f544338543bf053f9ce049/files/177eed168bd34a1c817af3b075e756e3.pdf. [4] HÜBSCHEN JM, GOUANDJIKA-VASILACHE I, DINA J. Measles[J]. Lancet, 2022, 399(10325):678-690. [5] LI X, GOODSON JL, PERRY RT.Measles Population Immunity Profiles:Updated Methods and Tools[J]. Vaccines (Basel), 2024, 12(8):937. [6] DURRHEIM DN.Measles eradication-retreating is not an option[J]. Lancet Infect Dis, 2020, 20(6):e138-e141. [7] O’CONNOR P, JANKOVIC D, MUSCAT M, et al. Measles and rubella elimination in the WHO Region for Europe:progress and challenges[J]. Clin Microbiol Infect, 2017, 23:504-510. [8] LAKSONO BM, DE VRIES RD, DUPREX WP,et al.Measles pathogenesis, immune suppression and animal models[J]. Curr Opin Virol, 2020, 41:31-37. [9] SCHENK J, ABRAMS S, THEETEN H, et al.Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines:a systematic review and meta-analysis[J]. Lancet Infect Dis, 2021, 21:286-295. [10] PORTNOY A, JIT M, FERRARI M, et al.Estimates of case-fatality ratios of measles in low-income and middle-income countries:a systematic review and modelling analysis[J]. Lancet Glob Health, 2019, 7:e472-e481. [11] ALLEN IV, MCQUAID S, PENALVA R, et al.Macrophages and dendritic cells are the predominant cells infected in measles in humans[J]. mSphere, 2018, 3:e00570-17. [12] CATTANEO R, DONOHUE RC, GENEROUS AR, et al.Stronger together:multi-genome transmission of measles virus[J]. Virus Res, 2019, 265:74-79. [13] 王禹,张玉林. 麻疹发病机制的研究进展[J]. 中华传染病杂志, 2022, 40(7):439-441. [14] LAKSONO BM, FORTUGNO P, NIJMEIJER BM, et al.Measles skin rash:infection of lymphoid and myeloid cells in the dermis precedes viral dissemination to the epidermis[J]. PLoS Pathog, 2020, 16:e1008253. [15] WILSON SE, SALVADORI MI, SCIENCE M.Measles[J]. CMAJ. 2024, 196(15):E524. [16] LAKSONO BM, DE VRIES RD, VERBURGH RJ, et al.Studies into the mechanism of measles-associated immune suppression during a measles outbreak in the Netherlands[J]. Nat Commun, 2018, 9:4944. [17] WRIGHT JR.Aldred Scott Warthin:Ann Arbor's Erudite, Outspoken, and Academically Transformative Early 20th Century Pathologist[J]. Arch Pathol Lab Med, 2021, 145(10):1297-1306. [18] KIMURA H, SHIRABE K, TAKEDA M, et al.The association between documentation of Koplik spots and laboratory diagnosis of measles and other rash diseases in a national measles surveillance program in Japan[J]. Front Microbiol, 2019, 10:269. [19] ANDREA LV, ANDRZE JK, CARLOTTA M, et al.Complications and risk factors for severe outcome in children with measles[J]. Arch Dis Child, 2020, 105(9):896-899. [20] RAGUSA R, PLATANIA A, CUCCIA M, et al.Measles and pregnancy:immunity and immunization—what can be learned from observing complications during an epidemic year[J]. J Pregnancy, 2020, 6532868. [21] CHARLIER C, DINA J, FREYMUTH F, et al.Prolonged maternal shedding and maternal-fetal transmission of measles virus[J]. Clin Infect Dis, 2021, 72:1631-1634. [22] GARG RK, MAHADEVAN A, MALHOTRA HS, et al.Subacute sclerosing panencephalitis[J]. Rev Med Virol, 2019, 29(5):e2058. [23] BROWN DW, WARRENER L, SCOBIE HM, et al.Rapid diagnostic tests to address challenges for global measles surveillance[J]. Curr Opin Virol, 2020, 41:77-84. [24] ROTA PA, EVANS R, BEN MAMOU MC, et al.The Global Measles and Rubella Laboratory Network Supports High-Quality Surveillance[J]. Vaccines (Basel), 2024, 12(8):946. [25] KUBA Y, NIDAIRA M, MAESHIRO N, et al.Analysis of suspected Measles cases with discrepant Measles-specific IgM and rRT-PCR test results, Japan[J]. Emerg Infect Dis, 2024, 30(5):926-933. [26] DINA J, OMNES J, VAULOUP-FELLOUS C, et al.True measles cases undetected by reverse transcription-PCR (RT-PCR):effect of genetic variability on assay sensitivity needs to be regularly surveyed[J]. J Clin Microbiol, 2019, 57:e00341-19. [27] WORLD HEALTH ORGANIZATION. Guide for clinical case management and infection prevention and control during a measles outbreak.2020[EB/OL]. https://apps.who.int/iris/handle/10665/331599. [28] GEORGE MS, KHAN HR, KHADKA S, et al.Measles resurgence in Armenia:unmasking health system vulnerabilities and crafting comprehensive eradication strategies - a review[J]. Ann Med Surg (Lond). 2024, 86(9):5394-5400. [29] WHO. Measles.In:Surveillance standards for vaccine-preventable diseases, 2nd edn. World Health Organization:Geneva, 2018[EB/OL].[2018-11-28]. https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_11_Measles_BW_R2.pdf?ua=1. [30] CONIS E.Measles and the modern history of vaccination[J]. Public Health Rep, 2019, 134:118-125. [31] GRIFFIN DE.Measles Vaccine[J]. Viral Immunol, 2018, 31:86-95. [32] DI PIETRANTONJ C, RIVETTI A, MARCHIONE P, et al. Vaccines for measles, mumps, rubella,varicella in children[J]. Cochrane Database Syst Rev, 2020, 4:CD004407. [33] WORLD HEALTH ORGANIZATION. WHO immunological basis for immunization series:module 7:measles. Update2020[EB/OL].[2020-02-12]. https://apps.who.int/iris/bitstream/handle/10665/331533/9789241516655-eng.pdf?sequence=1&isAllowed=y. [34] MATYSIAK-KLOSE D, SANTIBANEZ S, SCHWERDTFEGER C, et al.Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany[J]. Vaccine, 2018, 36:7916-7922. [35] DURRHEIM DN.Measles eradication—retreating is not an option[J]. Lancet Infect Dis, 2020, 20:e138-e141. |